Actemra IV (tocilizumab) / Roche, JW Pharma - LARVOL DELTA

Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma (TCT-ASTCT-CIBMTR 2026) - P1/2 | "One pt developed immune effector cell- associated hemophagocytic lymphohistiocytosis-like syndrome (Gr 2), which resolved after tocilizumab and anakinra treatment. Single-dose rapcabtagene autoleucel showed promising initial efficacy and a manageable safety profile in pts with 1L HR LBCL. Immunophenotyping and efficacy data for the final pt population with longer follow-up (≥6 mo for most pts) will be presented. Understand the initial safety and efficacy of rapcabtagene autoleucel (YTB323) in patients with large B-cell lymphoma who have received frontline chemoimmunotherapy"

Clinical • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Large B Cell Lymphoma • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rare Diseases • Thrombocytopenia • BCL2 • BCL6

Linking HLA-DRB1*15 to Severe Dress-like Inflammatory Toxicities Following Tocilizumab after CAR-T Therapy (TCT-ASTCT-CIBMTR 2026) - "Variables included HLA-DRB1 typing, exposure to tocilizumab (IL-6i) and/or anakinra (IL-1i), eosinophilia, organ-specific inflammation within 90 days of cytokine blockade, shock, rash, CRS, ICANS, and laboratory markers of systemic inflammation. This phenotype may contribute to refractory or delayed inflammatory complications, including IEC-HS. If validated, HLA-informed selection of cytokine-directed therapy, favoring short-acting IL-1 blockade over long-acting IL-6 inhibition in genetically susceptible patients, may represent a precision strategy to mitigate post-CAR toxicity."

IO biomarker • Late-breaking abstract • Acute Kidney Injury • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Eosinophilia • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Renal Disease • HLA-DRB1

Beta-Blocker Exposure and Immune Effector Toxicity after Myeloma Bispecific Antibodies: A Propensity-Matched Trinetx Study (TCT-ASTCT-CIBMTR 2026) - "However, its clinical impact during MM BsAb initiation is unknown.Objectives: To evaluate associations between baseline BB exposure and (1) grade ≥2 CRS, (2) CRS-directed therapy (tocilizumab), and (3) 1-year overall survival (OS) in MM patients initiating BsAbs. TriNetX Global Health Research Network was queried for adults with MM initiating commercial BsAbs (teclistamab, talquetamab, or elranatamab; index = first BsAb). In a propensity-matched real-world MM cohort initiating BsAbs, baseline BB exposure was not associated with clinically significant CRS (0–14 or 0–30 days), tocilizumab use, or 1-year OS. These data suggest concomitant BB therapy does not meaningfully alter early immune effector toxicity signals during BsAb initiation."

Late-breaking abstract • Asthma • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Diabetic Nephropathy • Heart Failure • Hematological Malignancies • Hypertension • Immune Modulation • Immunology • Inflammation • Metabolic Disorders • Multiple Myeloma • Myocardial Infarction • Nephrology • Renal Disease • Respiratory Diseases

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 (ASH 2025) - "Tocilizumab was administered prophylactically in the latter two patients after the first IRR was observed...No clinical sequelae of the lymphocytosis were noted; dexamethasone promptly resolved the lymphocytosis in the patient with the highest ALC... Preliminary results from the first three patients dosed in the inMMyCAR Phase 1 study of KLN-1010 demonstrate that promising clinical activity and manageable toxicities are feasible with an offthe-shelf in vivo CAR-T in MM. Lymphodepletion was not required for in vivo CAR-T cell generation and expansion in the peripheral blood. CRS was consistent with that seen with ex vivo CAR-T therapies, while cytopenias were notably limited and no treatment-emergent infections occurred."

First-in-human • Gene therapy • Late-breaking abstract • Minimal residual disease • P1 data • Preclinical • Residual disease • CNS Disorders • Dyslipidemia • Gene Therapies • Hematological Malignancies • Infectious Disease • Movement Disorders • Multiple Myeloma • Neutropenia • Parkinson's Disease • Thrombocytopenia

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial. (ASH 2025) - P1/2 | "Leukapheresis could be followed by further chemo-immunotherapy and then standard lymphodepletion (LD) with fludarabine-cyclophosphamide beforebrexucel infusion...Adverse events included cytokine release syndrome (CRS) in 8 (57%) pts (all grade 1); 3 pts neededsingle dose tocilizumab... From Dec 2024-July 31 2025, 28 pts have had leukapheresis,18 pts were infused and 14 pts with afollow-up (FU) >1 month post brexucel infusion were included in this report. The median age of theinfused pts was 35 years (range 19-77), and 5 pts (36%) were ³60 years of age. Ten pts (71%) receivedbrexcuel as FL consolidation therapy for adverse genomics, 3 FL pts (21%) had persistent (n=2)/recurrent(n=1) MRD, and 1 (7%) pt had R/R ALL."

Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Inflammation • Leukemia • KMT2A • TP53

Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study (ASH 2025) - "CRS primarily occurred in C1 and was mostly low Gr (Gr 1: 34.5%; Gr 2: 32.8%; Gr 3: 1.7%).Patients with CRS were frequently managed with tocilizumab (50.0%), steroids (67.5%), or both agents(32.5%); all events resolved. SC cevostamab monotherapy induces deep and durable responses and has manageablesafety in patients with late-line RRMM, many of whom had received prior BCMA-targeted therapies.Efficacy and safety (including CRS) appear generally comparable with that observed with IV cevostamabmonotherapy in patients with late-line RRMM, with the exception of the occurrence of low Gr ISRs."

Clinical • IO biomarker • P1 data • CNS Disorders • Dermatology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Pruritus • Thrombocytopenia

iMATRIX GLO: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=65 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Sep 2029 ➔ Nov 2032 | Trial primary completion date: May 2029 ➔ Nov 2029

Monotherapy • Trial completion date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD20 • CD4

Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC). (ASCO 2025) - P1 | "Pre-medication with dexamethasone (16 mg) was required in SU and 1st TD...Pts had a median of 4 prior therapies (range 1-13; 99.4% ARPI, 78.2% taxane chemotherapy, 17.2% lutetium Lu 177 vipivotide tetraxetan)...In the RP2D safety population (n=45; 3.5 mg [Day 1], 18 mg [Day 8], 300 mg Q3W or Q6W IV), the most common TRAEs were infusion-related reactions (22.2%; Gr 1/2), fatigue (15.6%; Gr 1/2), and CRS (8.9%; all Gr 1, no tocilizumab was administered), no TRAEs led to treatment discontinuation, no ICANS was observed, and 2 serious TRAEs (Gr 1 CRS) were reported... Pasritamig was very well tolerated (<10% of pts experienced CRS [all Gr1] at the RP2D) with promising antitumor activity, demonstrating proof of concept for KLK2 as a target amenable to T-cell redirection. These results address an unmet need for a targeted T-cell based therapy that is safe to administer in an outpatient setting with clinically meaningful benefit in mCRPC. Phase 3 trials are planned."

Metastases • P1 data • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • KLK2

Central Nervous System Demyelination Associated with TNF-Alpha inhibitors: A 20-Year Systematic Review (ACTRIMS Forum 2026) - "Certolizumab showed the earliest onset (mean 8.7 months, SD 13.2), adalimumab (mean 17.7, SD 16.3), etanercept (mean 22.5, SD 34.7), Infliximab (mean 27.7, SD 17.0), & golimumab (mean 32.2, SD 56.0)...For the neurological disorder, only 17.4% of patients required long-term management with disease-modifying therapy, most commonly rituximab (26%), ocrelizumab (15%), and glatiramer with interferon combination (15%)...Following TNF-alpha-inhibitor cessation, 29.03% experienced worsening of their systemic autoimmune condition & 9.6 % required alternative biological therapy, commonly secukinumab, ustekinumab, tocilizumab, or methotrexate... TNF-α inhibitors, though effective for autoimmune diseases, may unpredictably be associated with CNS demyelination. Most often linked with adalimumab, etanercept, and infliximab. While many patients recover after discontinuing steroids, some have persistent deficits, underscoring the need for cautious use and close neurological..."

Review • CNS Disorders • Immunology • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Reversal of chronic arterial stenosis with biologic therapy including tocilizumab in Takayasu arteritis. (PubMed, Mod Rheumatol Case Rep) - "Re-induction with methylprednisolone pulse and methotrexate (MTX) led to slight improvement. Subsequent therapy with tocilizumab (TCZ), followed by golimumab (GLM), resulted in significant and sustained improvement in the stenosis...Comprehensive disease assessment using imaging modalities, alongside serum biomarkers, is essential to guide therapeutic decisions and monitor vascular changes. These findings highlight the importance of imaging-based disease monitoring and raise the potential for targeted treatment strategies aimed at both inflammation control and vascular lesion modification."

Journal • Cardiovascular • Immunology • Inflammation • Vasculitis

Prevalence and Characteristics of CMV Reactivation after Chimeric Antigen Receptor T cell Therapy: A Referral Center Experience (TCT-ASTCT-CIBMTR 2026) - "Antiviral treatment was required in 28 patients, most commonly with valganciclovir, ganciclovir, or foscarnet N=17, 6, 5, respectively...Immune dysregulation, inflammatory cytokines, and T-cell dysfunction—exacerbated by steroids or anti-cytokine agents like tocilizumab or anakinra—may contribute...3. Identification of optimal timing and screening strategies for reactivation of CMV after CAR-T therapy."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Genetic Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Ophthalmology • Retinal Disorders

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines. (PubMed, CNS Drugs) - "For acute treatment: initiate high-dose intravenous methylprednisolone promptly and use plasma exchange early for severe or steroid-refractory attacks. For long-term immunotherapy, monoclonal antibodies (rituximab, inebilizumab, eculizumab, ravulizumab, satralizumab, or tocilizumab) are recommended according to availability and patient factors; conventional immunosuppressants remain alternatives when biologics are inaccessible. Guidance is provided for pediatric patients and for pregnancy and breastfeeding, including planning after ≥ 12 months of disease stability and early postpartum treatment resumption. These MENACTRIMS guidelines aim to improve NMOSD outcomes across the region by promoting accurate diagnosis and timely, effective therapy."

Journal • Review • CNS Disorders • Immunology • Multiple Sclerosis • Neuromyelitis Optica Spectrum Disorder • Pediatrics • Rare Diseases • Solid Tumor

Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicenter cohort of 526 patients. (PubMed, Rheumatology (Oxford)) - "Despite ABA therapy, progressive ILD occurred in nearly one-quarter of RA patients.ABA showed good tolerability and maintained pulmonary and rheumatologic stability in most cases. However, prior treatments and joint disease activity may help to predict the risk of ILD progression."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Stand UP to Rheumatoid Arthritis (SUPRA) (clinicaltrials.gov) - P=N/A | N=75 | Recruiting | Sponsor: Marie Hudson, MD | Trial completion date: Dec 2026 ➔ Dec 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2028

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Adalimumab, Anakinra and Tocilizumab in patients with non-infectious Uveitis: A multicenter randomized controlled trial. (PubMed, Am J Ophthalmol) - P2 | "Adalimumab and tocilizumab show comparable efficacy in active, refractory NIU, whereas anakinra was ineffective."

Journal • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis • Vasculitis

Safety And Effectiveness Of Tocilizumab In Systemic Sclerosis: A Multicenter French-Italian Study (SSWC 2026) - No abstract available

Clinical • Immunology • Scleroderma • Systemic Sclerosis

Analysis of the dynamics of clinical parameters and serum angiogenic factors in systemic sclerosis patients undergoing tocilizumab treatment (SSWC 2026) - No abstract available

Clinical • Immunology • Scleroderma • Systemic Sclerosis

Safety And Effectiveness Of Tocilizumab In Systemic Sclerosis: A Multicenter French-Italian Study (SSWC 2026) - No abstract available

Clinical • Immunology • Scleroderma • Systemic Sclerosis

GO39775: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov) - P1 | N=355 | Completed | Sponsor: Genentech, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ Jan 2026 | Trial primary completion date: Apr 2026 ➔ Jan 2026

Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

ROBUST LP(A) REDUCTION WITH COMBINED TOCILIZUMAB AND INCLISIRAN IN A HIGH-RISK INFLAMMATORY PATIENT (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. (PubMed, J Clin Oncol) - P3 | "Mosun-Pola demonstrated superior efficacy verus R-GemOx, with significant improvements in both overall response rate and progression-free survival, and infrequent cytokine release syndrome events with a manageable safety profile.(Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT05171647)."

Journal • P3 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma (ASH 2025) - P1, P1/2 | "Here, we report the combined data of these twostudies to provide long term follow up data of GC012F/AZD0120 in NDMM pts.Methods Eligible NDMM pts received a single infusion of GC012F/AZD0120 following two cycles lenalidomide,bortezomib and dexamethasone (RVd) induction therapy...GC012F/AZD0120 was administered at 4 dose levels:1x105/kg (n=1), 1.5x105/kg (n=3), 2x105/kg (n=4), or 3x105/kg (n=22) after a standard 3-daylymphodepletion regimen of fludarabine and cyclophosphamide...3 pts were treated with one dose of tocilizumab and 1 pt was treated with one dose oftocilizumab and corticosteroids...These promising results highlight the potential ofGC012F/AZD0120 CAR-T therapy for treating NDMM patients with HR features and transplant ineligibleNDMM pts. Further research with a larger patient population and extended follow-up is needed tovalidate these findings and address this critically unmet medical need."

Clinical • Hematological Malignancies • Inflammation • Multiple Myeloma • Plasmacytoma • PLAAT3

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study (ASH 2025) - P1/2 | "Whileadvances such as BCMA-directed CAR T-cell therapy have improved outcomes, challenges persist,including disease relapse, treatment toxicities (CRS, ICANS, and non-ICANS neurotoxicities), and access.AZD0120 (formerly GC012F) is a first-in-class autologous BCMA/CD19 dual-targeting CAR T-cell therapyusing the FasTCAR rapid manufacturing platform that preserves the naive and central memory T-cellphenotypes with marked in vivo proliferative capacity...The median age was 64 y (range 44–78), median pLOT was 4 (range 3–7), 72% were triple-classrefractory, 20% had prior BCMA CAR T-cell therapy, 4% had prior teclistamab, 28% had high-riskcytogenetic features [del(13q), del(17p13), t(4; 14), t(14; 16), amp(1q)], and 8% had extramedullaryplasmacytomas...Median timeto CRS onset (DL1/DL2) was 9 d (range 2–11), with a median duration of 2 d (range 1–4); 12 pts (48%)received tocilizumab for CRS management and 12% received dexamethasone... Preliminary phase 1b results..."

CAR T-Cell Therapy • Clinical • P1/2 data • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Multiple Myeloma • Plasmacytoma

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma (ASH 2025) - P1 | "In cohortswithout (received 100 mg Q4W) and with (received 100 mg Q4W/Q8W) prophylactic tocilizumab, CRSoccurred in 69.2% (gr 2, 15.4%) and 20.0% (gr 2, 0%), respectively. With longer follow-up in part 1 of the phase 1 trial, JNJ-5322 continues to demonstrateresponses comparable to CAR-T therapy (ORR 100.0%) that are durable and continue to deepen (≥CR77.8%), with a safety profile similar or improved compared with BsAbs targeting BCMA or GPRC5D. JNJ-5322 offers off-the-shelf, Q4W dosing and 1 SUD with low rates of gr 2 CRS that may enable an efficientapproach to dual antigen targeting via convenient administration and outpatient treatment. Thesefindings support further evaluation of JNJ-5322 in patients with RRMM."

Clinical • IO biomarker • Trispecific • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases

OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study (ASH 2025) - P1 | "We report preliminary data from an ongoing phase I, first-in-human, dose-escalation and dose-expansion study (NCT06644118). Patients with R/R MM who had received ≥3 prior lines of therapies underwent standardlymphodepletion (fludarabine/cyclophosphamide) followed by a single OL-101 infusion at 3 dose levels(DL1: 1.0×106, DL2: 2.0×106, DL3: 1.5×106 cells/kg)...At the 2.0×106 cells/kg dose level, 1 of 6 patientsexperienced a DLT, manifested as grade 4 CRS with onset on Day 3 post-infusion, which resolved by Day17 following treatment with tocilizumab, steroids, plasma exchange and other supportive care... OL-101, a novel bispecific BCMA/GPRC5D VHH CAR-T, demonstrates promising efficacy (100%ORR, 100% MRD negativity) and manageable safety (CRS manageable, no ICANS) in heavily pretreated,triple-class exposed R/R MM patients, with no new safety signals identified than those with previouslyreported BCMA or GPRC5D targeting CAR-T cells. Notably,..."

IO biomarker • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia • GPRC5D